TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
Delayed Japan Exchange  -  02:00 2022-06-24 am EDT
3707.00 JPY   +0.05%
06/24Takeda Pharmaceutical to Absorb Businesses From Unit Nihon Pharmaceutical
MT
06/22Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation Efforts
BU
06/22Takeda Signs 15-Year Lease with BioMed Realty
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

05/11/2022 | 02:00am EDT

Takeda Pharmaceutical Company Limited provided consolidated earnings guidance for the fiscal year ending March 31, 2023. The company expects revenue to be JPY 3,690,000 million, Operating profit to be JPY 520,000 million, net profit attributable to owners of parent to be JPY 292,000 million or JPY 188.13 per basic share.


© S&P Capital IQ 2022
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
06/24Takeda Pharmaceutical to Absorb Businesses From Unit Nihon Pharmaceutical
MT
06/22Takeda Announces Creation of One Cambridge Campus in Kendall Square to Drive Innovation..
BU
06/22Takeda Signs 15-Year Lease with BioMed Realty
CI
06/17MARKETSCREENER'S WORLD PRESS REVIEW : June 17, 2022
06/17Takeda, Nintendo among Japanese firms quietly celebrating weak yen
RE
06/10Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Th..
AQ
06/10TAKEDA PHARMACEUTICAL : Notice Concerning Disposal of Treasury Shares under the Long-Term ..
PU
06/09Takeda Pharmaceutical Says Dengue Vaccine Candidate 84% Effective Against Hospitalizati..
MT
06/09Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Th..
BU
06/07Takeda Canada applauds Quebec's new Rare Disease Policy
AQ
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 490 B 25 833 M 25 833 M
Net income 2022 239 B 1 768 M 1 768 M
Net Debt 2022 3 299 B 24 416 M 24 416 M
P/E ratio 2022 24,2x
Yield 2022 4,86%
Capitalization 5 722 B 42 353 M 42 353 M
EV / Sales 2022 2,58x
EV / Sales 2023 2,33x
Nbr of Employees 47 099
Free-Float 96,8%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 3 707,00 JPY
Average target price 4 468,13 JPY
Spread / Average Target 20,5%
EPS Revisions
Managers and Directors
Christophe Weber Chief Operating & Corporate Officer
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED18.11%42 353
JOHNSON & JOHNSON5.02%462 443
ELI LILLY AND COMPANY17.88%276 070
PFIZER, INC.-15.17%275 327
ABBVIE INC.12.51%260 755
ROCHE HOLDING AG-19.20%259 627